Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
The use of intramuscular (15S)-15-methyl prostaglandin F2 alpha (Prostin/15 M [The Upjohn Company, Kalamazoo, Michigan] sterile solution; carboprost tromethamine) for termination of pregnancy between six and 24 weeks' gestation was studied by 20 investigators. Of 815 women treated according to the dosage regimen described here, 78.4% had complete abortions and 18.0% incomplete abortions, for an overall success rate of 96.4%. The majority of patients had vomiting and diarrhea but usually tolerated these side effects well enough that treatment did not have to be discontinued. There were no serious adverse reactions directly attributable to the prostaglandin therapy.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!